The U.S. Food and Drug Administration (FDA) is clarifying dosing and warning recommendations for the antidepressant Celexa ( citalopram hydrobromide ; also available in generic form).

The U.S. Food and Drug Administration (FDA) is updating the public on the use of selective serotonin reuptake inhibitor ( SSRI ) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as persistent pulmonary hypertension of the newborn ( PPHN ).

The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa ( citalopram hydrobromide ; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Studies did not show a benefit in the treatment of depression at doses higher than 40 mg per day.

The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa ( citalopram hydrobromide ; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Studies did not show a benefit in the treatment of depression at doses higher than 40 mg per day. Previously, the citalopram drug label stated that certain patients may require a dose of 60 mg per day. Facts about Celexa ( citalopram hydrobromide ) Is in a cla...

The U.S. Food and Drug Administration (FDA) has received reports of serious central nervous system (CNS) reactions when the drug methylene blue is given to patients taking psychiatric medications that work through the serotonin system of the brain ( serotonergic psychiatric medications).

Viibryd has just been approved by the FDA to treat adults with major depression, a mental disorder which affects around 15 million people in the United States.